FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Arthur M. Krieg et al.	
Sheet 1 of 2	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		5,646,126		Cheng et al.	07-08-1997
		7,279,555	B2	Peterson	10-09-2007
		7,521,063	B2	Klinman et al.	04-21-2009
		7,566,703	B2	Krieg et al.	07-28-2009
		7,569,553	B2	Krieg	08-04-2009
		7,576,066	B2	Krieg	08-18-2009
		7,585,847	B2	Bratzler et al.	09-08-2009
		7,605,138	B2	Krieg	10-20-2009
		7,615,539	B2	Krieg et al.	11-10-2009
		7,666,674	B2	Klinman et al.	02-23-2010
		7,674,777	B2	Krieg	03-09-2010
		7,713,529	B2	Krieg et al.	05-11-2010
		7,276,489	B2	Agrawal et al.	10-02-2007
		7,723,022	B2	Krieg et al.	05-25-2010
		7,723,500	B2	Krieg et al.	05-25-2010
		7,776,344	B2	Hartmann et al.	08-17-2010
		2005-0026861	A1	Kandimalla et al.	02-03-2005
		2009-0074851	A1	Bachmann et al.	03-19-2009
		2009-0155212	A1	Bratzler et al.	06-18-2009
		2009-0191188	A1	Krieg et al.	07-30-2009
		2009-0202575	A1	Krieg et al.	08-13-2009
		2009-0214578	A1	Bauer	08-27-2009
		2009-0306177	A1	Uhlmann et al.	12-10-2009
		2009-0311277	A1	Krieg	12-17-2009
		2010-0125101	A1	Krieg et al.	05-20-2010
		2010-0166780	A1	Debelak et al.	07-01-2010
		2010-0183639	A1	Uhlmann et al.	07-22-2010

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document Office/ Country	Foreign Patent Document Number	Foreign Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		WO	94/08053	A1	ISIS Pharmaceuticals, Inc.	04-14-1994	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
				APPLICANT: Arthur M. Krieg et al.	
Sheet	2	of	2	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

		WO	00/41720	A1	CSL Limited	07-20-2000	
		WO	01/51083	A2	Aquila Biopharmaceuticals, Inc.	07-19-2001	
		WO	01/54720	A1	Cistem Biotechnologies-Gmbh	08-02-2001	
		WO	03/040308	A2	The Government of the United States of America	05-15-2003	
		WO	03/085110	A2	Cureon A/S	10-16-2003	
		WO	2005/013891	A2	Juvaris Biotherapeutics, Inc.	02-17-2005	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		AGRAWAL, Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):53-68. Review.	
		AZUMA et al., Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol. 2001 Jul;1(7):1249-59. Review.	
		FEARON et al., A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur J Immunol. 2003 Aug;33(8):2114-22.	
		IOANNOU et al., CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine. 2002: 21; 127-37.	
		JORGENSEN et al., CpG DNA induces protective antiviral immune responses in Atlantic salmon (Salmo salar L.). J Virol. 2003 Nov;77(21):11471-9.	
		KRIEG et al., Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. Antisense Nucleic Acid Drug Dev. 1997 Apr;7(2):115-23.	
		SAMANI et al., Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):129-36.	
		SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
		UHLMANN et al., Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol. 2000;313:268-84.	
		UHLMANN, Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. Expert Opin Biol Ther. 2001 Mar;1(2):319-28.	
		WAHLESTEDT et al., Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5633-8.	
		YU et al., Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem. 2001 Nov;9(11):2803-8.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.